A consensus of positive sentiment continues to surround IQVIA Holdings Inc., the global provider of advanced analytics and clinical research services to the life sciences industry. The prevailing view among research firms remains a “Moderate Buy,” a stance reinforced by a recent and significant price target revision.
Solid Fundamentals Underpin Analyst Confidence
The optimistic ratings are grounded in the company’s recent financial performance. For the third quarter of 2025, IQVIA reported revenue of $4.1 billion, representing a 5.2% year-over-year increase. Adjusted earnings per share came in at $3.00. Both metrics exceeded market expectations. The company has also reaffirmed its full-year 2025 profit guidance and anticipates long-term revenue growth in the mid-single-digit percentage range.
Strategic initiatives are further strengthening the investment thesis. A recently announced collaboration with Amazon Web Services to leverage artificial intelligence for automating clinical trials underscores IQVIA’s commitment to technological leadership, a key factor noted by observers.
Should investors sell immediately? Or is it worth buying Iqvia?
Stifel Nicolaus Raises Target Price Substantially
A notable vote of confidence arrived from Stifel Nicolaus this week. The firm’s analyst, Shlomo Rosenbaum, not only reiterated a “Buy” rating but also lifted the price target considerably from $254 to $273. This adjustment followed discussions with company management and reflects an expectation for a sustained recovery in the life sciences sector, projected to extend through 2026.
Broad Consensus for a “Moderate Buy” Recommendation
The bullish call from Stifel is part of a wider trend. According to a current consensus summary, a commanding majority of covering analysts recommend purchasing the stock. Of the 22 firms providing ratings, the collective recommendation stands at “Moderate Buy.” This is comprised of sixteen “Buy” or “Strong Buy” ratings alongside six “Hold” recommendations. The average price target across all analysts is approximately $243.58.
The upcoming quarterly results will be closely watched for confirmation that the data and research services provider remains on its projected growth trajectory.
Ad
Iqvia Stock: Buy or Sell?! New Iqvia Analysis from December 18 delivers the answer:
The latest Iqvia figures speak for themselves: Urgent action needed for Iqvia investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 18.
Iqvia: Buy or sell? Read more here...
